SCHEMBL6489308

SCHEMBL6489308

CC(C)(C)OC(=O)N1C(Cc2ccc(Oc3ccnc4cc(Cl)ccc34)cc2)COC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.40
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
MET P08581 2/20 0.38
AXL P30530 2/20 0.38
IDE P14735 2/20 0.38
MERTK Q12866 1/20 0.38
PDGFRA P16234 4/20 0.37
KDR P35968 3/20 0.37
APP P05067 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
BRD4 O60885 1/20 0.37
CLK1 P49759 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489302 1.00 HSD17B10 (0.41) HSD17B10SMN1; SMN2LMNAALDH1A1GLA
SCHEMBL6492398 0.89 SSTR4 (0.39) METAXLMERTKPDGFRAKDR
SCHEMBL6486930 0.84 BRD4 (0.46) SMN1; SMN2ALDH1A1MEN1KMT2ABRD4
SCHEMBL6486940 0.84 BRD4 (0.46) SMN1; SMN2ALDH1A1MEN1KMT2ABRD4
SCHEMBL7692131 0.81 MET (0.39) METAXLMERTKPDGFRAKDR
SCHEMBL6480073 0.79 P2RX3 (0.37)
SCHEMBL6480120 0.79 P2RX3 (0.37)
SCHEMBL6481261 0.79 CARM1 (0.43) HSD17B10SMN1; SMN2LMNAALDH1A1MAPT
SCHEMBL6481265 0.79 CARM1 (0.43) HSD17B10SMN1; SMN2LMNAALDH1A1MAPT
SCHEMBL18290259 0.78 IDE (0.40) HSD17B10SMN1; SMN2LMNAALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043358-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-02-24 US disclosed
US-20020143034-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143034-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB1, ADRB2, ADRB3 HSD17B10 511/4885SMN1; SMN2 3719/4885LMNA 626/4885
US-20050043358-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB2, ADRB1, ADRB3 HSD17B10 801/4885SMN1; SMN2 3736/4885LMNA 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.